SEC-sourced researchBeta
IBRX
ImmunityBio, Inc.
Company comparison ↗
Data passport
- CIK
- 0001326110
- Exchange
- Nasdaq
- Business activity
- — · SIC 2836
- Financial inputs
- 6/6
- Filing date
- Oct 6, 2026
- SEC registry record
- Operating company
Annual financial history
Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table.
| Period end | Revenue | Filing date |
|---|---|---|
| December 2023 | 622,000.0000 | Feb 23, 2026 |
| December 2024 | 14,745,000.0000 | Feb 23, 2026 |
| December 2025 | 113,288,000.0000 | Feb 23, 2026 |
Annual periods · USD
| Period end | Revenue | Net income | Operating cash flow | Total assets | Total liabilities | Filing date |
|---|---|---|---|---|---|---|
| December 2025 | 113,288,000.0000 | -351,398,000.0000 | -304,936,000.0000 | 501,898,000.0000 | 1,001,472,000.0000 | Feb 23, 2026 |
| December 2024 | 14,745,000.0000 | -413,564,000.0000 | -391,236,000.0000 | 382,933,000.0000 | 871,062,000.0000 | Feb 23, 2026 |
| December 2023 | 622,000.0000 | -583,196,000.0000 | -366,757,000.0000 | — | — | Feb 23, 2026 |
Financial inputs behind the calculation
| Financial inputs | USD | Period end | Filing date | Form |
|---|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $113.29M | December 2025 | Feb 23, 2026 | 10-K |
| Previous period revenueRevenueFromContractWithCustomerExcludingAssessedTax | $14.75M | December 2024 | Feb 23, 2026 | 10-K |
| Net incomeNetIncomeLoss | -$351.4M | December 2025 | Feb 23, 2026 | 10-K |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | -$304.94M | December 2025 | Feb 23, 2026 | 10-K |
| Total assetsAssets | $501.9M | December 2025 | Feb 23, 2026 | 10-K |
| Total liabilitiesLiabilities | $1B | December 2025 | Feb 23, 2026 | 10-K |